Breaking Finance News

RBC Capital announced SAGE Therapeutics (NASDAQ:SAGE), bumping up its stock price target to $117.00 today

In a statement issued on Friday September 15, 2017 RBC Capital upped the target of SAGE Therapeutics (NASDAQ:SAGE) to $117.00 stating a potential upside of 0.81%.

On 9/13/2017, Needham released a statement on SAGE Therapeutics (NASDAQ:SAGE) dropped the target price from $95.00 to $86.00 that suggested an upside of 0.13%.

Showing a price of $64.81, SAGE Therapeutics (NASDAQ:SAGE) traded -2.10% lower on the day. The last stock price is down -15.20% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same period. SAGE has recorded a 50-day average of $81.85 and a 200-day moving average of $74.87. 473,504 shares of SAGE traded hands, down from an average trading volume of 527,362

Recent Performance Chart

SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics has 52 week low of $38.30 and a 52 week high of $90.80 and has a market capitalization of $0.

In addition to RBC Capital reporting its stock price target, a total of 8 brokerages have issued a ratings update on the company. The average stock price target is $68.88 with 0 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.